CCR Live Program 2025

Update on CD19-Targeted CAR T-cell Therapy to Treat Severe Refractory Systemic Lupus Erythematosus (SLE)

1. Which of the following statements is false?

2. An advantage of CAR T-cell treatment in systemic lupus erythematosus (SLE) is:

3. A major disadvantage of autologous CAR T-cell treatment in SLE is:

Name

First NameLast Name

Email

example@example.com

What is your license?

If PharmD, DOB

Date

If PharmD, NABP ID#

What is your specialty?

What is your practice setting?

Other

How many patients do you typically see each month?

Please rate the extent to which this activity met the following objectives:

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Review the pathophysiology and mode of action of CAR T-cell therapy
Review the current clinical options, unmet needs, and emerging therapies for patients with severe, refractory systemic lupus erythematosus
Analyze the clinical trial data and clinical applications of CAR T-cell therapy to treat patients with severe, refractory SLE
Develop strategies to incorporate patient shared decision making when discussing CAR T-cell therapy for SLE

Please provide us with feedback regarding your experience at the activity:

Please rate the faculty on their overall teaching ability:

Rows	Poor	Fair	Good	Very Good	Excellent
Joan Merrill, MD

Do you feel this activity was fair balanced and free of commercial bias?

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

What factors beyond clinical care that effect the health of your patients does your team experience?

Date

Attestation: This activity is certified for a maximum of 1.5 AMA PRA Category 1 Credits™.

I participated in this activity and claim _______ credit(s).

POST-TEST ASSESSMENT